Your browser doesn't support javascript.
loading
Hepatitis C-associated Osteosclerosis (HCAO): Long-Term Follow-Up of a New Case Recovered After Antiviral Treatment.
Arcidiacono, Gaetano Paride; Poci, Carlo; Sella, Stefania; Torres, Marco Onofrio; Zanchetta, Francesca; Cecchinato, Alberta; Diogo, Martin; Peleg Falb, Mor; Giannini, Sandro.
Afiliação
  • Arcidiacono GP; Department of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy. gaetano.arcidiacono@unipd.it.
  • Poci C; Department of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
  • Sella S; Department of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
  • Torres MO; Department of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
  • Zanchetta F; Department of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
  • Cecchinato A; Department of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
  • Diogo M; Department of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
  • Peleg Falb M; Department of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
  • Giannini S; Department of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
Calcif Tissue Int ; 113(5): 571-577, 2023 11.
Article em En | MEDLINE | ID: mdl-37718324
ABSTRACT
Hepatitis C-associated osteosclerosis (HCAO) is a very rare condition that can be observed in a small number of patients with Hepatitis C Virus (HCV) infection. HCAO is usually characterized by widespread bone sclerosis, associated with severe bone pain, and increased levels of bone turnover markers, especially alkaline phosphatase (ALP). In this report, we present the case of a 55-year-old woman who was affected by HCV and came to our attention for severe and diffuse bone pain. Radiological studies showed bone sclerosis, and bone mineral density (BMD) was markedly increased, as well as serum ALP levels. The patient was initially treated with intravenous pamidronate, which provided only a transient benefit on clinical symptoms. Then antiviral therapy for HCV (interferon-alfa and ribavirin) was started and it was effective in making the viral load undetectable. After a long follow-up period, we observed a persistent remission of bone pain, a reduction in BMD together with a progressive trend toward the normalization of bone turnover markers. In conclusion, HCAO, although rare, should be considered among the potential causes of increased bone mass in patients with HCV infection, and treatment for the underlying infection may be effective in controlling the manifestations of this disease.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteosclerose / Hepatite C Tipo de estudo: Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteosclerose / Hepatite C Tipo de estudo: Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article